Treatment of hidradenitis suppurativa using JAK inhibitors
US12280054B2 · kind B2 · utility
0Cited by
123References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 13, 2022 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | May 2, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.